Rapamycin combined with donor immature dendritic cells promotes liver allograft survival in association with CD4 +CD25 +Foxp3 + regulatory T cell expansion

Hepatology Research

Volumn 42, Issue 2, 2012, Pages 192-202

  Wang, Guo Ying ^a   Yang, Yang ^a   Li, Hua ^a   Zhang, Jian ^a   Li, Min Ru ^a   Zhang, Qi ^b   Chen, Gui Hua ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Provincial Key Laboratory of Liver Disease Research   (China)

Author keywords

Dendritic cells; Immune tolerance; Liver transplantation; Rapamycin; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT REJECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL POPULATION; CONTROLLED STUDY; DENDRITIC CELL; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; LIVER GRAFT; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MALE; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; RECIPIENT; REGULATORY T LYMPHOCYTE; SPLEEN;

EID: 84862934566     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00909.x     Document Type: Article

References (53)

1. Barratt-Boyes SM, Thomson AW. Dendritic cells: tools and targets for transplant tolerance. Am J Transplant 2005; 5: 2807-13.
2. Coenen JJ, Koenen HJ, van Rijssen E etal. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 2007; 39: 537-45.
3. Segundo DS, Ruiz JC, Izquierdo M etal. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006; 82: 550-7.
4. Coenen JJ, Koenen HJ, van Rijssen E etal. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107: 1018-23.
5. Singh AK, Horvath KA, Mohiuddin MM. Rapamycin promotes the enrichment of CD4(+)CD25(hi)FoxP3(+) T regulatory cells from naive CD4(+) T cells of baboon that suppress antiporcine xenogenic response in vitro. Transplant Proc 2009; 41: 418-21.
6. Du JF, Li SY, Yu B. Rapamycin - rather than FK506 - might promote allograft tolerance induced by CD4+CD25+ regulatory T cells. Surgery 2009; 146: 526-7; author reply 7-8.
7. Uss E, Yong SL, Hooibrink B etal. Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro. Transplantation 2007; 83: 1098-106.
8. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005; 105: 4743-8.
9. Zeiser R, Leveson-Gower DB, Zambricki EA etal. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008; 111: 453-62.
10. Cheng J, Zhou L, Qin YS etal. Donor apoptotic lymphocyte transfusion-induced liver allograft tolerance by up-regulation of CD4(+)CD25(+) regulatory T cells in peripheral blood. Transplant Proc 2009; 41: 3893-7.
11. Fujiki M, Esquivel CO, Martinez OM etal. Induced tolerance to rat liver allografts involves the apoptosis of intragraft T cells and the generation of CD4(+)CD25(+)FoxP3(+) T regulatory cells. Liver Transpl 2010; 16: 147-54.
12. Wang GY, Chen GH, Li H etal. Rapamycin-treated mature dendritic cells have a unique cytokine secretion profile and impaired allostimulatory capacity. Transpl Int 2009; 22: 1005-16.
13. Wang GY, Chen GH, Li H etal. Rapamycin inhibits activator protein-1 but not nuclear factor-kappaB activity of mature bone marrow-derived dendritic cells. Transplant Proc 2010; 42: 1881-3.
14. Kamada N, Calne RY. Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation 1979; 28: 47-50.
15. Fontenot JD, Rasmussen JP, Gavin MA etal. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6: 1142-51.
16. Zorn E, Nelson EA, Mohseni M etal. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-9.
17. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
18. Khattri R, Cox T, Yasayko SA etal. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4: 337-42.
19. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007; 8: 457-62.
20. Abe Y, Urakami H, Ostanin D etal. Induction of Foxp3-expressing regulatory T-cells by donor blood transfusion is required for tolerance to rat liver allografts. PLoS ONE 2009; 4: e7840.
21. Demirkiran A, Hendrikx TK, Baan CC etal. Impact of immunosuppressive drugs on CD4+CD25+FOXP3+ regulatory T cells: does in vitro evidence translate to the clinical setting? Transplantation 2008; 85: 783-9.
22. Kreijveld E, Koenen HJ, Hilbrands LB etal. The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+ CD25- T cells. Blood 2007; 109: 244-52.
23. Battaglia M, Stabilini A, Draghici E etal. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 2006; 55: 40-9.
24. Keever-Taylor CA, Browning MB, Johnson BD etal. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 2007; 9: 144-57.
25. Kopf H, de la Rosa GM, Howard OM etal. Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells. Int Immunopharmacol 2007; 7: 1819-24.
26. Battaglia M, Stabilini A, Migliavacca B etal. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338-47.
27. Game DS, Hernandez-Fuentes MP, Lechler RI. Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant 2005; 5: 454-64.
28. Basu S, Golovina T, Mikheeva T etal. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180: 5794-8.
29. Chen JF, Gao J, Zhang D etal. CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro. Chin Med J (Engl) 2010; 123: 942-8.
30. Valmori D, Tosello V, Souleimanian NE etal. Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells. J Immunol 2006; 177: 944-9.
31. Zeiser R, Nguyen VH, Beilhack A etal. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-9.
32. Mita A, Ricordi C, Miki A etal. Anti-proinflammatory effects of sirolimus on human islet preparations. Transplantation 2008; 86: 46-53.
33. Hackstein H, Taner T, Logar AJ etal. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084-7.
34. Matsue H, Yang C, Matsue K etal. Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation. J Immunol 2002; 169: 3555-64.
35. Monti P, Mercalli A, Leone BE etal. Rapamycin impairs antigen uptake of human dendritic cells. Transplantation 2003; 75: 137-45.
36. Hackstein H, Taner T, Zahorchak AF etal. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457-63.
37. Woltman AM, van der Kooij SW, Coffer PJ etal. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003; 101: 1439-45.
38. Taner T, Hackstein H, Wang Z etal. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5: 228-36.
39. Turnquist HR, Raimondi G, Zahorchak AF etal. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178: 7018-31.
40. Horibe EK, Sacks J, Unadkat J etal. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol 2008; 18: 307-18.
41. Woltman AM, de Fijter JW, Kamerling SW etal. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001; 98: 174-80.
42. Chiang PH, Wang L, Bonham CA etal. Mechanistic insights into impaired dendritic cell function by rapamycin: inhibition of Jak2/Stat4 signaling pathway. J Immunol 2004; 172: 1355-63.
43. Sordi V, Bianchi G, Buracchi C etal. Differential effects of immunosuppressive drugs on chemokine receptor CCR7 in human monocyte-derived dendritic cells: selective upregulation by rapamycin. Transplantation 2006; 82: 826-34.
44. Turnquist HR, Sumpter TL, Tsung A etal. IL-1beta-driven ST2L expression promotes maturation resistance in rapamycin-conditioned dendritic cells. J Immunol 2008; 181: 62-72.
45. Mirenda V, Berton I, Read J etal. Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004; 15: 987-97.
46. Thornton AM. Signal transduction in CD4+CD25+ regulatory T cells: CD25 and IL-2. Front Biosci 2006; 11: 921-7.
47. Yamazaki S, Iyoda T, Tarbell K etal. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2003; 198: 235-47.
48. DePaz HA, Oluwole OO, Adeyeri AO etal. Immature rat myeloid dendritic cells generated in low-dose granulocyte macrophage-colony stimulating factor prolong donor-specific rat cardiac allograft survival. Transplantation 2003; 75: 521-8.
49. Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells. J Immunol 2005; 174: 7433-9.
50. van Duivenvoorde LM, van Mierlo GJ, Boonman ZF etal. Dendritic cells: vehicles for tolerance induction and prevention of autoimmune diseases. Immunobiology 2006; 211: 627-32.
51. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. Nat Immunol 2001; 2: 1010-17.
52. Nakamura I, Kajino K, Bamba H etal. Phenotypic stability of mature dendritic cells tuned by TLR or CD40 to control the efficiency of cytotoxic T cell priming. Microbiol Immunol 2004; 48: 211-19.
53. D'Cruz L, Klein L. Development and function of agonist-induced CD25+ Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005; 6: 1152-9.